Langsjoen P H, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P
Department of Medicine, Scott and White Clinic, Temple, Texas.
Klin Wochenschr. 1988 Jul 1;66(13):583-90. doi: 10.1007/BF01720833.
Coenzyme Q10 (CoQ10) is indispensable in mitochondrial bioenergetics and for human life to exist. 88/115 patients completed a trial of therapy with CoQ10 for cardiomyopathy. Patients were selected on the basis of clinical criteria, X-rays, electrocardiograms, echocardiography, and coronary angiography. Responses were monitored by ejection fractions, cardiac output, and improvements in functional classifications (NYHA). Of the 88 patients 75%-85% showed statistically significant increases in two monitored cardiac parameters. Patients with the lowest ejection fractions (approx. 10%-30%) showed the highest increases (115 delta %-210 delta %) and those with higher ejection fractions (50%-80%) showed increases of approx. 10 delta %-25 delta % on therapy. By functional classification, 17/21 in class IV, 52/62 in class III, and 4/5 in class II improved to lower classes. Clinical responses appeared over variable times, and are presumably based on mechanisms of DNA-RNA-protein synthesis of apoenzymes which restore levels of CoQ10 enzymes in a deficiency state. 10/21 (48%) of patients in class IV, 26/62 (42%) in class III, and 2/5 (40%) in class II had exceptionally low control blood levels of CoQ10. Clinical responses on therapy with CoQ10 appear maximal with blood levels of approx. 2.5 micrograms CoQ10/ml and higher during therapy.
辅酶Q10（CoQ10）在线粒体生物能量学以及人类生命存在方面不可或缺。115名患者中有88名完成了辅酶Q10治疗心肌病的试验。患者根据临床标准、X线、心电图、超声心动图和冠状动脉造影进行选择。通过射血分数、心输出量和功能分级（纽约心脏协会分级）的改善来监测反应。在这88名患者中，75%-85%的患者在两项监测的心脏参数上有统计学显著增加。射血分数最低（约10%-30%）的患者增加幅度最大（115% - 210%），而射血分数较高（50%-80%）的患者在治疗中增加幅度约为10% - 25%。按功能分级，IV级中的17/21、III级中的52/62和II级中的4/5改善到了更低级别。临床反应出现在不同时间，推测是基于脱辅基酶的DNA - RNA - 蛋白质合成机制，该机制在缺乏状态下恢复辅酶Q10酶的水平。IV级患者中有10/21（48%）、III级患者中有26/62（42%）以及II级患者中有2/5（40%）的辅酶Q10对照血水平异常低。辅酶Q10治疗的临床反应在治疗期间血水平约为2.5微克辅酶Q10/毫升及更高时似乎最大。
